NeuroBo Pharmaceuticals (NRBO) Competitors $0.85 +0.04 (+4.55%) As of 04/24/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NRBO vs. BTCS, ARBK, WVFC, KFFB, MOGO, PNBK, GLBZ, JFU, SHFS, and ANYShould you be buying NeuroBo Pharmaceuticals stock or one of its competitors? The main competitors of NeuroBo Pharmaceuticals include BTCS (BTCS), Argo Blockchain (ARBK), WVS Financial (WVFC), Kentucky First Federal Bancorp (KFFB), Mogo (MOGO), Patriot National Bancorp (PNBK), Glen Burnie Bancorp (GLBZ), 9F (JFU), SHF (SHFS), and Sphere 3D (ANY). These companies are all part of the "banking" industry. NeuroBo Pharmaceuticals vs. BTCS Argo Blockchain WVS Financial Kentucky First Federal Bancorp Mogo Patriot National Bancorp Glen Burnie Bancorp 9F SHF Sphere 3D NeuroBo Pharmaceuticals (NASDAQ:NRBO) and BTCS (NASDAQ:BTCS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, community ranking, media sentiment, dividends, institutional ownership, valuation and profitability. Does the MarketBeat Community prefer NRBO or BTCS? NeuroBo Pharmaceuticals received 21 more outperform votes than BTCS when rated by MarketBeat users. However, 100.00% of users gave BTCS an outperform vote while only 75.00% of users gave NeuroBo Pharmaceuticals an outperform vote. CompanyUnderperformOutperformNeuroBo PharmaceuticalsOutperform Votes2775.00% Underperform Votes925.00% BTCSOutperform Votes6100.00% Underperform VotesNo Votes Which has more volatility and risk, NRBO or BTCS? NeuroBo Pharmaceuticals has a beta of -0.26, meaning that its share price is 126% less volatile than the S&P 500. Comparatively, BTCS has a beta of 2.9, meaning that its share price is 190% more volatile than the S&P 500. Do analysts recommend NRBO or BTCS? NeuroBo Pharmaceuticals currently has a consensus price target of $10.00, suggesting a potential upside of 1,076.47%. BTCS has a consensus price target of $5.00, suggesting a potential upside of 161.78%. Given NeuroBo Pharmaceuticals' higher possible upside, equities research analysts plainly believe NeuroBo Pharmaceuticals is more favorable than BTCS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeuroBo Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00BTCS 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is NRBO or BTCS more profitable? BTCS has a net margin of 366.80% compared to NeuroBo Pharmaceuticals' net margin of 0.00%. BTCS's return on equity of -15.42% beat NeuroBo Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets NeuroBo PharmaceuticalsN/A -189.12% -122.31% BTCS 366.80%-15.42%-13.77% Do institutionals and insiders hold more shares of NRBO or BTCS? 1.4% of NeuroBo Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.5% of BTCS shares are owned by institutional investors. 1.1% of NeuroBo Pharmaceuticals shares are owned by insiders. Comparatively, 42.8% of BTCS shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has higher earnings and valuation, NRBO or BTCS? BTCS has higher revenue and earnings than NeuroBo Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeuroBo PharmaceuticalsN/AN/A-$12.47MN/AN/ABTCS$4.07M7.50$7.82M-$0.22-8.68 Does the media prefer NRBO or BTCS? In the previous week, BTCS had 2 more articles in the media than NeuroBo Pharmaceuticals. MarketBeat recorded 2 mentions for BTCS and 0 mentions for NeuroBo Pharmaceuticals. BTCS's average media sentiment score of 0.84 beat NeuroBo Pharmaceuticals' score of 0.00 indicating that BTCS is being referred to more favorably in the news media. Company Overall Sentiment NeuroBo Pharmaceuticals Neutral BTCS Positive SummaryBTCS beats NeuroBo Pharmaceuticals on 11 of the 13 factors compared between the two stocks. Get NeuroBo Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NRBO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRBO vs. The Competition Export to ExcelMetricNeuroBo PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.32M$6.68B$5.44B$7.80BDividend YieldN/A3.17%5.43%4.30%P/E RatioN/A7.1422.1418.40Price / SalesN/A238.89389.70101.29Price / CashN/A65.6738.2034.62Price / Book0.576.266.664.18Net Income-$12.47M$142.48M$3.21B$247.71M7 Day Performance15.02%7.90%6.16%6.56%1 Month Performance-46.20%-4.23%-2.86%-2.25%1 Year Performance-72.58%-2.70%16.43%4.67% NeuroBo Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRBONeuroBo PharmaceuticalsN/A$0.85+4.6%$10.00+1,076.5%-72.2%$7.32MN/A0.0010High Trading VolumeBTCSBTCS3.3119 of 5 stars$1.59-3.6%$5.00+214.5%+32.6%$25.45M$4.07M3.884Gap UpARBKArgo Blockchain1.1899 of 5 stars$0.33-5.3%N/A-73.9%$23.69M$60.03M-0.4640Gap DownWVFCWVS FinancialN/A$12.29flatN/AN/A$23.28M$5.13M12.5420KFFBKentucky First Federal Bancorp0.8181 of 5 stars$2.60-5.5%N/A-33.8%$21.92M$8.01M-18.5760Positive NewsMOGOMogo2.5358 of 5 stars$0.80flat$4.00+398.8%-47.9%$19.63M$71.21M-1.71350News CoveragePNBKPatriot National Bancorp1.9244 of 5 stars$4.03+22.9%N/A+8.4%$16.02M$31.10M-0.54130News CoveragePositive NewsGap DownHigh Trading VolumeGLBZGlen Burnie Bancorp1.211 of 5 stars$5.22+0.2%N/A+1.5%$15.14M$11.77M-130.5080JFU9F1.3594 of 5 stars$1.10+3.8%N/A-63.3%$12.95M$295.14M0.00740Positive NewsGap DownSHFSSHF0.5218 of 5 stars$4.19+87.9%N/A-72.3%$11.67M$17.87M24.653Gap DownHigh Trading VolumeANYSphere 3D2.6918 of 5 stars$0.45-4.3%$3.00+573.2%-49.4%$11.67M$16.61M-0.5620Analyst ForecastNews Coverage Related Companies and Tools Related Companies BTCS Alternatives Argo Blockchain Alternatives WVS Financial Alternatives Kentucky First Federal Bancorp Alternatives Mogo Alternatives Patriot National Bancorp Alternatives Glen Burnie Bancorp Alternatives 9F Alternatives SHF Alternatives Sphere 3D Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NRBO) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroBo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroBo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NRBO Stock Free NRBO Stock Alerts